Kansai Medical University Hospital Initiates First Patient Dose of DS1025 in Global Phase 1 Trial

DS1025: Pioneering Phase 1 Clinical Trial at Kansai Medical University Hospital

On August 18, 2026, a major milestone in cancer treatment research was achieved as Kansai Medical University Hospital administered the first dose of DS1025 to a patient. This event marks the beginning of a global Phase 1 clinical trial pioneered by Daiichi Sankyo. The Department of New Experimental Therapeutics, led by Professor Toshio Shimizu, is at the forefront of this groundbreaking study, which aims to assess the safety and efficacy of a revolutionary drug aimed at combating advanced solid tumors.

DS1025 is categorized as a CD25 directed Antibody-Drug Conjugate (ADC)—a novel therapeutic approach seeking to enhance the body's immune response against cancer cells. The drug targets CD25, which is predominantly expressed on Treg cells that suppress immune responses against tumors. By utilizing this mechanism, DS1025 has the potential to deplete these immunosuppressive T-cells, thereby activating the immune system to better detect and destroy cancer cells.

The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DS1025 in patients who have advanced or metastatic solid tumors and have progressed after at least one standard line of therapy. This multicenter, open-label clinical trial is structured to include up to 45 adult participants whose conditions are deemed unsuitable for further standard treatments.

In celebrating the successful administration of the first dose, the team at Kansai Medical University Hospital recognizes their increasing role in international cancer drug development, particularly in a region where access to early-phase clinical trials has been notably limited. Working closely with Daiichi Sankyo and other global partners, they aim to contribute significantly to the advancement of cancer treatment methodologies.

The trial will assess various important endpoints: primary endpoints will focus on safety and tolerability, including the evaluation of dose-limiting toxicities and adverse events. Secondary endpoints will address pharmacokinetics and the immune response generated by the treatment. Moreover, exploratory endpoints will measure the overall response rate, duration of response, and time to response—key indicators of DS1025's potential effectiveness.

As Kansai Medical University approaches its centennial anniversary in 2028, its commitment to advancing clinical research and developing innovative cancer therapies remains paramount. Underpinned by its founding dedication to benevolence, compassion, and empathy, the University is dedicated to nurturing skilled medical professionals and leading initiatives that aim to transform patient outcomes in healthcare.

As the trial unfolds, many eyes will be watching the results from Kansai Medical University, as success could pave the way for new and effective treatments for patients battling cancer. It reaffirms the University’s status as a critical player in early-stage clinical trials in Asia and globally, as they seek to redefine the future of oncology.

For more information about this clinical trial, you can refer to ClinicalTrials.gov.